These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 19276671)
41. Epidermal growth factor receptor (EGFR) antibody-induced antibody-dependent cellular cytotoxicity plays a prominent role in inhibiting tumorigenesis, even of tumor cells insensitive to EGFR signaling inhibition. Overdijk MB; Verploegen S; van den Brakel JH; Lammerts van Bueren JJ; Vink T; van de Winkel JG; Parren PW; Bleeker WK J Immunol; 2011 Sep; 187(6):3383-90. PubMed ID: 21832160 [TBL] [Abstract][Full Text] [Related]
42. An anti‑TROP2 monoclonal antibody TrMab‑6 exerts antitumor activity in breast cancer mouse xenograft models. Tanaka T; Ohishi T; Asano T; Takei J; Nanamiya R; Hosono H; Sano M; Harada H; Kawada M; Kaneko MK; Kato Y Oncol Rep; 2021 Jul; 46(1):. PubMed ID: 34013368 [TBL] [Abstract][Full Text] [Related]
43. Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects. Zhang W; Zhu XD; Sun HC; Xiong YQ; Zhuang PY; Xu HX; Kong LQ; Wang L; Wu WZ; Tang ZY Clin Cancer Res; 2010 Jul; 16(13):3420-30. PubMed ID: 20570927 [TBL] [Abstract][Full Text] [Related]
46. Antitumor activity of humanized monoclonal antibody against HM1.24 antigen in human myeloma xenograft models. Kawai S; Yoshimura Y; Iida S; Kinoshita Y; Koishihara Y; Ozaki S; Matsumoto T; Kosaka M; Yamada-Okabe H Oncol Rep; 2006 Feb; 15(2):361-7. PubMed ID: 16391855 [TBL] [Abstract][Full Text] [Related]
47. Development and Ma XH; Wang S; Liu SY; Chen K; Wu ZY; Li DF; Mi YT; Hu LB; Chen ZW; Zhao XM World J Gastroenterol; 2019 Jun; 25(24):3030-3043. PubMed ID: 31293339 [TBL] [Abstract][Full Text] [Related]
48. Development of a Time-Resolved Fluorescence Immunoassay for the Diagnosis of Hepatocellular Carcinoma Based on the Detection of Glypican-3. Chen JJ; Xie CM; Wang CR; Wan Y; Dong ZN; Li M; Xu WW J Fluoresc; 2017 Jul; 27(4):1479-1485. PubMed ID: 28429175 [TBL] [Abstract][Full Text] [Related]
49. In vitro and in vivo characterization of MDX-1401 for therapy of malignant lymphoma. Cardarelli PM; Moldovan-Loomis MC; Preston B; Black A; Passmore D; Chen TH; Chen S; Liu J; Kuhne MR; Srinivasan M; Assad A; Witte A; Graziano RF; King DJ Clin Cancer Res; 2009 May; 15(10):3376-83. PubMed ID: 19401346 [TBL] [Abstract][Full Text] [Related]
50. Plasmodium parasite as an effective hepatocellular carcinoma antigen glypican-3 delivery vector. Liu Q; Yang Y; Tan X; Tao Z; Adah D; Yu S; Lu J; Zhao S; Qin L; Qin L; Chen X Oncotarget; 2017 Apr; 8(15):24785-24796. PubMed ID: 28445973 [TBL] [Abstract][Full Text] [Related]
51. Inhibition of murine hepatoma tumor growth by cryptotanshinone involves TLR7-dependent activation of macrophages and induction of adaptive antitumor immune defenses. Han Z; Liu S; Lin H; Trivett AL; Hannifin S; Yang D; Oppenheim JJ Cancer Immunol Immunother; 2019 Jul; 68(7):1073-1085. PubMed ID: 31161238 [TBL] [Abstract][Full Text] [Related]
52. A Novel Vaccine Targeting Glypican-3 as a Treatment for Hepatocellular Carcinoma. Wu Q; Pi L; Le Trinh T; Zuo C; Xia M; Jiao Y; Hou Z; Jo S; Puszyk W; Pham K; Nelson DR; Robertson K; Ostrov D; Rameshwar P; Xia CQ; Liu C Mol Ther; 2017 Oct; 25(10):2299-2308. PubMed ID: 28865999 [TBL] [Abstract][Full Text] [Related]
53. Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes. Sawada Y; Yoshikawa T; Shimomura M; Iwama T; Endo I; Nakatsura T Int J Oncol; 2015 Jan; 46(1):28-36. PubMed ID: 25354479 [TBL] [Abstract][Full Text] [Related]
54. Glypican-3 deficiency in liver cancer upregulates MAPK/ERK pathway but decreases cell proliferation. Chung JY; Lee W; Lee OW; Ylaya K; Nambiar D; Sheehan-Klenk J; Fayn S; Hewitt SM; Choyke PL; Escorcia FE Am J Cancer Res; 2024; 14(7):3348-3371. PubMed ID: 39113871 [TBL] [Abstract][Full Text] [Related]
55. A Novel, Fully Human Anti-fucosyl-GM1 Antibody Demonstrates Potent Ponath P; Menezes D; Pan C; Chen B; Oyasu M; Strachan D; LeBlanc H; Sun H; Wang XT; Rangan VS; Deshpande S; Cristea S; Park KS; Sage J; Cardarelli PM Clin Cancer Res; 2018 Oct; 24(20):5178-5189. PubMed ID: 30021910 [No Abstract] [Full Text] [Related]
56. [Construction and function of Glypican-3-targeted fourth-generation chimeric antigen receptor T cells (secreting IL-7 and CCL19)]. Huang W; Liu Y; Hu Y; Gao J Sheng Wu Gong Cheng Xue Bao; 2020 May; 36(5):979-991. PubMed ID: 32567281 [TBL] [Abstract][Full Text] [Related]
57. Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30. Oflazoglu E; Stone IJ; Gordon KA; Grewal IS; van Rooijen N; Law CL; Gerber HP Blood; 2007 Dec; 110(13):4370-2. PubMed ID: 17909075 [TBL] [Abstract][Full Text] [Related]
58. Development of GPC3-CAR-NK cells and optimization as a therapy for HCC. Cao B; Ni Q; Chen Z; Yang S; Zhang X; Su H; Zhang Z; Zhao Q; Zhu X; Liu M J Leukoc Biol; 2024 Jun; ():. PubMed ID: 38922297 [TBL] [Abstract][Full Text] [Related]
59. Inhibition by monosaccharides of tumor associated macrophages mediated antibody dependent cell cytotoxicity to autologous tumor cells. Chattopadhyay U; Bhattacharyya S Neoplasma; 1987; 34(3):295-303. PubMed ID: 3614464 [TBL] [Abstract][Full Text] [Related]
60. Antitumor activity of an anti-CD98 antibody. Hayes GM; Chinn L; Cantor JM; Cairns B; Levashova Z; Tran H; Velilla T; Duey D; Lippincott J; Zachwieja J; Ginsberg MH; H van der Horst E Int J Cancer; 2015 Aug; 137(3):710-20. PubMed ID: 25556716 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]